Patient capital for the
scientists rebuilding
medicine itself.
Taiho Ventures is the corporate venture arm of Taiho Pharmaceutical — an R&D-driven company with a sixty-year history of putting customers first and a pledge to "improve human health and contribute to a society enriched by smiles."
We back early-stage founders developing first-in-class therapeutics, novel platform biology, and the modalities that will define the next decade of oncology, immunology, and rare disease. We hold for the long arc — and we bring the operating muscle of a global pharmaceutical to every check we write.
Where we invest.
Four areas, one filter — does this work compound the science Taiho has spent decades building?
Drug Discovery
First-in-class small molecules, biologics, and gene/cell therapies grounded in new biology.
Platform Tech
Foundational platforms that compress the path from target to clinic.
Spin-outs
Strategic carve-outs from Taiho's own pipeline — assets ready for an independent journey.
Devices & Dx
Opportunistic investments across diagnostics, devices, and digital health.
The companies we've backed.
Who reads the round.
We strive to improve human health and contribute to a society enriched by smiles.
The pledge is sixty years old. It is also what governs every term sheet we issue, every board seat we take, and every founder we choose to walk alongside.
Submit a company.
Five fields and a paragraph. We answer every brief in five business days — including no. If we want a deeper conversation, we will write back with a time.